company background image
TBP

Tetra Bio-PharmaTSX:TBP Stock Report

Market Cap

CA$100.4m

7D

-10.7%

1Y

72.4%

Updated

26 Sep, 2021

Data

Company Financials
TBP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TBP Overview

Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs.

Price History & Performance

Summary of all time highs, changes and price drops for Tetra Bio-Pharma
Historical stock prices
Current Share PriceCA$0.25
52 Week HighCA$0.14
52 Week LowCA$0.53
Beta2.19
1 Month Change-18.03%
3 Month Change-27.54%
1 Year Change72.41%
3 Year Change-78.99%
5 Year Change11.11%
Change since IPO900.00%

Recent News & Updates

Sep 14
Does Tetra Bio-Pharma (TSE:TBP) Have A Healthy Balance Sheet?

Does Tetra Bio-Pharma (TSE:TBP) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

TBPCA PharmaceuticalsCA Market
7D-10.7%1.8%-0.3%
1Y72.4%39.6%30.8%

Return vs Industry: TBP exceeded the Canadian Pharmaceuticals industry which returned 39.6% over the past year.

Return vs Market: TBP exceeded the Canadian Market which returned 30.8% over the past year.

Price Volatility

Is TBP's price volatile compared to industry and market?
TBP volatility
TBP Beta2.19
Industry Beta1.84
Market Beta1

Stable Share Price: TBP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: TBP's weekly volatility has decreased from 15% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a31Guy Chamberlandhttps://www.tetrabiopharma.com

Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. It develops ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; Reduvo for chemotherapy-induced nausea and vomiting; PLENITUDE to treat advanced uncontrolled cancer pain; REBORN for the treatment of breakthrough cancer pain and fibromyalgia; and SERENITY to treat cancer cachexia. The company also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.

Tetra Bio-Pharma Fundamentals Summary

How do Tetra Bio-Pharma's earnings and revenue compare to its market cap?
TBP fundamental statistics
Market CapCA$100.42m
Earnings (TTM)-CA$28.36m
Revenue (TTM)n/a

0x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TBP income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
ExpensesCA$28.36m
Earnings-CA$28.36m

Last Reported Earnings

May 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.071
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio8.4%

How did TBP perform over the long term?

See historical performance and comparison

Valuation

Is Tetra Bio-Pharma undervalued compared to its fair value and its price relative to the market?

2.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TBP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TBP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TBP is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: TBP is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TBP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TBP is overvalued based on its PB Ratio (2.8x) compared to the CA Pharmaceuticals industry average (2.5x).


Future Growth

How is Tetra Bio-Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

44.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tetra Bio-Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Tetra Bio-Pharma performed over the past 5 years?

-47.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TBP is currently unprofitable.

Growing Profit Margin: TBP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TBP is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.

Accelerating Growth: Unable to compare TBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).


Return on Equity

High ROE: TBP has a negative Return on Equity (-79.22%), as it is currently unprofitable.


Financial Health

How is Tetra Bio-Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: TBP's short term assets (CA$17.8M) exceed its short term liabilities (CA$5.2M).

Long Term Liabilities: TBP's short term assets (CA$17.8M) exceed its long term liabilities (CA$3.0M).


Debt to Equity History and Analysis

Debt Level: TBP's debt to equity ratio (8.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TBP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TBP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.7% each year


Dividend

What is Tetra Bio-Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TBP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TBP's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Guy Chamberland (59 yo)

3.42yrs

Tenure

CA$471,796

Compensation

Dr. Guy Chamberland, M.Sc., Ph D., Master Herbalist, serves as Chief Executive Officer and Chief Regulatory Officer at Tetra Bio-Pharma Inc. since October 15, 2018 and serves as its Director since June 20,...


CEO Compensation Analysis

Compensation vs Market: Guy's total compensation ($USD371.65K) is above average for companies of similar size in the Canadian market ($USD161.55K).

Compensation vs Earnings: Guy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TBP's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: TBP's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.5%.


Top Shareholders

Company Information

Tetra Bio-Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Tetra Bio-Pharma Inc.
  • Ticker: TBP
  • Exchange: TSX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$100.417m
  • Shares outstanding: 401.67m
  • Website: https://www.tetrabiopharma.com

Number of Employees


Location

  • Tetra Bio-Pharma Inc.
  • 2316 St. Joseph Boulevard
  • Orléans
  • Ontario
  • K1C 1E8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:20
End of Day Share Price2021/09/24 00:00
Earnings2021/05/31
Annual Earnings2020/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.